Cargando…

In silico prediction of bioequivalence of atorvastatin tablets based on GastroPlus™ software

The prediction of intestinal absorption of various drugs based on computer simulations has been a reality. However, in vivo pharmacokinetic simulations and virtual bioequivalence evaluation based on GastroPlus™ have not been found. This study aimed to simulate plasma concentrations with different di...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lu, Chen, Jinliang, Chen, Wenjun, Ruan, Zourong, Lou, Honggang, Yang, Dandan, Jiang, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685666/
https://www.ncbi.nlm.nih.gov/pubmed/38017512
http://dx.doi.org/10.1186/s40360-023-00689-4
_version_ 1785151685174231040
author Wang, Lu
Chen, Jinliang
Chen, Wenjun
Ruan, Zourong
Lou, Honggang
Yang, Dandan
Jiang, Bo
author_facet Wang, Lu
Chen, Jinliang
Chen, Wenjun
Ruan, Zourong
Lou, Honggang
Yang, Dandan
Jiang, Bo
author_sort Wang, Lu
collection PubMed
description The prediction of intestinal absorption of various drugs based on computer simulations has been a reality. However, in vivo pharmacokinetic simulations and virtual bioequivalence evaluation based on GastroPlus™ have not been found. This study aimed to simulate plasma concentrations with different dissolution profiles and run population simulations to evaluate the bioequivalence of test and reference products of atorvastation using GastroPlus software. The dissolution profiles of the reference and test products of atorvastatin (20 mg tablets), and clinical plasma concentration-time data of the reference product were used for the simulations. The results showed that the simulated models were successfully established for atorvastatin tablets. Population simulation results indicated that the test formulation was bioequivalent to the reference formulation. The findings suggest that modelling is an essential tool to demonstrating the possibility of pharmacokinetic and bioequivalence for atorvastatin. It will contribute to understanding the potential risks during the development of generic products.
format Online
Article
Text
id pubmed-10685666
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106856662023-11-30 In silico prediction of bioequivalence of atorvastatin tablets based on GastroPlus™ software Wang, Lu Chen, Jinliang Chen, Wenjun Ruan, Zourong Lou, Honggang Yang, Dandan Jiang, Bo BMC Pharmacol Toxicol Research The prediction of intestinal absorption of various drugs based on computer simulations has been a reality. However, in vivo pharmacokinetic simulations and virtual bioequivalence evaluation based on GastroPlus™ have not been found. This study aimed to simulate plasma concentrations with different dissolution profiles and run population simulations to evaluate the bioequivalence of test and reference products of atorvastation using GastroPlus software. The dissolution profiles of the reference and test products of atorvastatin (20 mg tablets), and clinical plasma concentration-time data of the reference product were used for the simulations. The results showed that the simulated models were successfully established for atorvastatin tablets. Population simulation results indicated that the test formulation was bioequivalent to the reference formulation. The findings suggest that modelling is an essential tool to demonstrating the possibility of pharmacokinetic and bioequivalence for atorvastatin. It will contribute to understanding the potential risks during the development of generic products. BioMed Central 2023-11-28 /pmc/articles/PMC10685666/ /pubmed/38017512 http://dx.doi.org/10.1186/s40360-023-00689-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wang, Lu
Chen, Jinliang
Chen, Wenjun
Ruan, Zourong
Lou, Honggang
Yang, Dandan
Jiang, Bo
In silico prediction of bioequivalence of atorvastatin tablets based on GastroPlus™ software
title In silico prediction of bioequivalence of atorvastatin tablets based on GastroPlus™ software
title_full In silico prediction of bioequivalence of atorvastatin tablets based on GastroPlus™ software
title_fullStr In silico prediction of bioequivalence of atorvastatin tablets based on GastroPlus™ software
title_full_unstemmed In silico prediction of bioequivalence of atorvastatin tablets based on GastroPlus™ software
title_short In silico prediction of bioequivalence of atorvastatin tablets based on GastroPlus™ software
title_sort in silico prediction of bioequivalence of atorvastatin tablets based on gastroplus™ software
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685666/
https://www.ncbi.nlm.nih.gov/pubmed/38017512
http://dx.doi.org/10.1186/s40360-023-00689-4
work_keys_str_mv AT wanglu insilicopredictionofbioequivalenceofatorvastatintabletsbasedongastroplussoftware
AT chenjinliang insilicopredictionofbioequivalenceofatorvastatintabletsbasedongastroplussoftware
AT chenwenjun insilicopredictionofbioequivalenceofatorvastatintabletsbasedongastroplussoftware
AT ruanzourong insilicopredictionofbioequivalenceofatorvastatintabletsbasedongastroplussoftware
AT louhonggang insilicopredictionofbioequivalenceofatorvastatintabletsbasedongastroplussoftware
AT yangdandan insilicopredictionofbioequivalenceofatorvastatintabletsbasedongastroplussoftware
AT jiangbo insilicopredictionofbioequivalenceofatorvastatintabletsbasedongastroplussoftware